Bortezomib is an important proteasome inhibitor widely used in plasma cell neoplasms. An acute cardiac dysfunction is not a frequent side effect of bortezomib, but it is mentioned in literature search via multiple case reports. We have discussed here, another case of a young male diagnosed with plasma cell leukemia on treatment, presenting with sudden onset dyspnea due to an acute myocardial toxicity which subsequently upon thorough evaluation turned out to be an association with cyclical bortezomib administration.
INTRODUCTION

Bortezomib (Velcade
is linked with cardiac dysfunction in multiple case reports but no association is determined by any clinical study up till now. It is FDA approved as a first choice drug for multiple myeloma and in patients with mantle cell lymphoma who should have received at least one prior therapy. Bortezomib is known to reversibly block the proteosomal activity in cancer cells and as well as normal body cells including cardiac myocytes. Most cases of heart failure secondary to inherited cardiomyopathies exhibit accumulation of ubiquitinated proteins, abnormal protein aggregation such as pre-amyloid oligomers, and altered proteasomal activities [1] . An exact mechanism of bortezomib-induced cardiac dysfunction and a reason for cardiac myocytes vulnerability for this acquired, drug induced proteasome inhibition is still unexplored.
Here we present a case of plasma cell leukaemia that developed sudden onset systolic left ventricle dysfunction after treatment with bortezomib.
CASE REPORT
A 44-year-old male, known to have hypothyroidism since last 6 years with no other comorbidity and risks for cardiac illness, presented to the outpatient service. He had a history of high-grade febrile episodes associated with a sore throat and mild non-productive cough for one week and *Address correspondence to this author at the Haematology and Internal Medicine, Stem Cell Research and Regenerative Medicine, Haematologist and Transplant Physician, HEC Approved PhD Supervisor, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan, Email: tahir.shamsi@nibd.edu.pk unintentional weight reduction of 4 kilograms in one month. His CBC done a week earlier showed abnormal circulating lympho-cytes. His past medical and surgical history were unremarkable. There was no history of any blood transfusions. He has been on levothyroxine 100mcg per day. At this dose, he was maintaining normal TSH status. He was a non-smoker and never indulged in any substance abuse. There had not been any travel abroad in the preceding year. His mother was diabetic. Review of systems did not reveal anything beside weight loss. His general physical and systemic examination was absolutely fine with no finding in any system at all.
His initial tests done at the time of presentation to us, Hb 10.2 g/dl, TLC 97 x 10 9 /dl, ANC 0.3 x 10 9 /l, ALC 78 x 10 9 /l and Platelets 49 x 10 9 /l. His flowcytometric analysis on peripheral blood yielded 79.5 x 10 9 (80%) circulating plasma cells confirming the diagnosis of plasma cell leukemia. His bone marrow analysis showed infiltration by plasmacytoid cells. There was no monoclonal band on serum protein electrophoresis. FISH analysis for del 17p was negative. Renal and liver functions were normal at baseline.
He received a combination of bortezumib, leno ledamide, dexamethasone and cyclophosphamide for this treatment [2] [3] [4] . The total dose of bortezomib was 19.2 mg/m 2 and the cumulative dose of cyclophosphamide 2.4 g/ m 2 over 24 weeks was given. Adjuvant antimicrobial prophylaxis against fungal, viral and Pneumocystis jiroveci pneumonia was also given. He achieved hematological remission 6 months since his treatment despite being started. There was 0.03% corresponding with On the basis of the absent ST-T changes on ECG, negative cardiac biomarkers, and global hypokinesia on echocardiography which are not a feature of acute myocardial infarction, dilated cardiomyopathy was suspected as a case of an acute heart failure.
DIFFERENTIAL DIAGNOSIS
Normal thyroid profile essentially excludes occult thyrotoxicosis or myxedema as a reason for an underlying heart failure while an absence of ST segment and T wave changes and negative troponin results raises the suspicion of an acute myocarditis. An absence of fever, upper respiratory illness, high white cell count, pleuritic or pericardial chest pain and recent vaccination excludes a viral myocarditis. Due to an absence of any associated factors for a dilated cardiomyopathy besides drug toxicity and echocardiographic findings exhibiting gross systolic dysfunction and aberrant myocardial expansion, an underlying drug-related cardio-
FINAL CLINICAL DIAGNOSIS
Since cyclophophamide in cyclical low doses (less than 1.5 g/m 2 ) is not associated with systolic LV dysfunction through clinical studies [2] [3] [4] , the most likely diagnosis in our case was Bortezomib induced LV systolic dysfunction.
POST EVENT FOLLOW-UP
His systolic dysfunction persisted after a follow-up echocardiogram after one year with an improvement in ejection fraction I.e. 30-35 %. He is ambulatory and able to perform the routine daily activity. He has rejoined his office job recently and has been started on lenalidomide, melphalan and dexamethasone as his maintenance chemotherapy. He is still enjoying remission and his underlying cardiac function has greatly improved now.
DISCUSSION
Bortezomib is associated with systolic LV dysfunction in many case reports in literature. The incidence of cardiac dysfunction described in a Journal of American College Cardiology 2009 is 1-5% [5] . Bortezomib is dipeptide boronic acid that acts as a proteasome inhibitor inside the cells. It impairs the activation of NF-ĸB, which is important for cell survival. Through NF-ĸB inhibition bortezomib inhibits bcl-2 phosphorylation and breakdown, causing G2-M phase cell cycle arrest, hence cellular apotosis [6, 7] . A growing body of evidence indicates impairment of the ubiqitin proteosome system in inherited cardiomyopathies as determined by measurement of the level of ubiquitinated proteins, the activities of the proteasome and/or the use of fluorescent UPS reporter substrates [1] . A similar mechanism might propose an acquired cardiomyopathy induced by cellular inhibition of proteomes via bortezomib. Whether this is an underlying cause or not a thorough search warrants further exploration into the exact mechanism of cardiac dysfunction induced by bortezomib. A study on rats so far has produced left ventricular contractile dysfunction manifested by a significant drop in left ventricle ejection fraction when they were subjected to bortezomib administration [6] . A literature search done for the various reported cases 7-14 of systolic heart dysfunction induced by bortezomib shows the average threshold level of cardiac dysfunction happening to be around total dose beyond 20 mg/m2 in individuals with de novo heart failure. In postevent follow-ups mentioned in those case studies there is an evidence of improvement in the cardiac function after bortezomib discontinuation.
There is no established consensus at present to recommend the preemptive measures to be taken before initiation of bortezomib, for detection of an underlying asymptomatic cardiac dysfunction [5] . It is logical to get an echocardiogram done if there are associated cardiac risk factors (smoking, diabetes, hypertension and hyperlipidemia) or history of an underlying cardiac disease and patients should be counseled for the possibility of this important adverse effect before suggesting bortezomib cycles for their underlying malignant disorder. There also should be a further study in the role of cardiac MRI, radio-nuclear scanning, cardiac biopsy or other sophisticated diagnostic tools in these cancer patients, in order to reach an exact pathologic diagnosis in this sudden post chemotherapyinduced systolic LV dysfunction.
CONCLUSION
Bortezomib has an adverse side effect of LV systolic dysfunction that should be born in mind when dealing with any individual receiving it. A slight hint of chronic fatigue or shortness of breath on exertion observed in any patient before, during or after receiving bortezomib should be taken into an account, and a thorough evaluation is recommended.
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